Although rhEPO together with recombinant IGF were tested for the ability to prevent the loss of vasculature during the first phase of retinopathy of prematurity, studies on the role of genetic components, NO, adenosine, apelin, and β-adrenergic receptor have opened up new opportunities for retinopathy treatment [69]. This evidence concerns the gene IGF1 and retinal disorder.